Audit: QRS - Barberry for Health & Longevity
Audit conducted on 04/09/2026 04:23 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All benefit/risk tier items, gate items, protocol cells, time-to-effect cells, all 12 monitoring rows and all 5 qualitative items map 1:1 onto ER headings, bullets and table rows. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | The ER’s ⚠️ Conflicted markers are carried as “(conflicted)”; time_3_sub reuses “the evidence base is a single trial, so replication is absent” (ER line 171). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Pregnancy stays an absolute Contraindication; the four conflicted findings retain their conflict flag; the single-trial endothelial result is labelled as such. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | All 9 stop_items and 11 caution_items originate in the ER Key Interactions & Contraindications section; no Benefit- or Risk-Modifying Factor was promoted into a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS contains no PMIDs, author names, NCT identifiers or brand names at all. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Plain-language registers such as “fasting sugar” and “artery widening” are lifted from the ER’s own wording (ER lines 163, 171). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Neutral, evidence-first register throughout; contested findings are named as contested rather than dismissed. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Gate items name populations and agents; no directive is issued to any individual. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Content is stated descriptively; the only imperative-adjacent sentence, “Nothing measurable should be expected inside a month”, is ER verbatim (ER line 429). |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No instance of recommend/advise/should-do phrasing in the document’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun occurs anywhere in the rendered content. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are limited to the monitoring markers, where precision is required; the At-A-Glance is entirely plain. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate item is label-only; benefit and risk tiers are semicolon-joined single lines; protocol subs run to at most two sentences. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | The 12-marker panel, the interaction list and the baseline-dependence framing address a proactive optimizer. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Three distinct dosing approaches, split dosing with meals, and a full baseline plus 12-week panel presuppose that willingness. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Apolipoprotein B, HOMA-IR and blood lead are non-routine tests aimed well past general-population practice. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The At-A-Glance leads with what is steady versus contradictory, and marker_5_why (“Detects both benefit and over-correction”) speaks to an already-optimized reader. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the page title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Cell labels are formal (“Endothelial function changes”, “Concentrated extract approach”); the plainer terms used are the ER’s own. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | All fixed strings match the template byte-for-byte (QRS lines 446, 492, 543, 573, 591, 620, 648, 652-654, 827). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variable names are present; the only additions are the expected repeated instances of the marker_#* and qualitative_item# row patterns. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three hooks, the CSS block, the print rules and the footer disclaimer are byte-identical to the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section feeding the QRS is empty; every benefit tier, risk tier and gate list is populated. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | action_1/2/3_label reproduce the ER Protocol bold labels “Whole-fruit approach”, “Concentrated extract approach” and “Berberine-standardized root approach” exactly (ER lines 372-376). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels track the ER’s own nouns in ER line 429 (“Lipid changes”, “glucose changes”, “endothelial function changes”). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | A codepoint scan for pictographic ranges returns no match; the ER’s tier squares and ⚠️ markers were dropped in favour of the template’s CSS palette and bold tier labels. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every optional element is condensed — 57-word At-A-Glance, two-sentence protocol subs, label-only gate items, and marker_12_target trimmed from 20 words to 13 while keeping the 3.5 µg/dL threshold. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The comment opens at line 2, immediately after the doctype, and precedes the template comment at line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13; the descriptive text on line 2 sits before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | It is inside an HTML comment and no value is echoed anywhere in the body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values are trimmed; only duration: "00:03" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: barberry_2026-0904-0011_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0904-0416, in the required format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version with no trailing qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: barberry_2026-0904-0011_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace and no unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Barberry for Health & Longevity - Quick Reference Sheet”, with the ampersand entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Barberry for Health & Longevity”, matching ER frontmatter canonical_topic (ER line 8). |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “09/04/2026”, the correct MM/DD/YYYY rendering of 2026-0904. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header holds only the title and the template subline; the ER’s “Also known as” line was correctly not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Every clause traces to ER Conclusion lines 504-508: the two-part shrub framing, the fruit-dominated short trials in one country, the steady lipid and glucose findings, the contradictory blood pressure and weight results, and the two over-weighted harms. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 57 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Five sentences map to five distinct Conclusion passages with no synthesis beyond them. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “blood fats”, “fasting blood sugar” and “digestive upset” replace triglycerides, fasting glucose and gastrointestinal intolerance. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No study name, year, participant count or p-value appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric effect estimate, confidence interval or odds ratio appears. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items come from that section — eight from the “Populations who should avoid Barberry” list (ER lines 343-350) and one from the berberine-supplement bullet (ER line 331). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight avoid-populations plus the absolute berberine-stacking contraindication are present; none is omitted. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Nine discrete <li> elements at QRS lines 576-586. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every “given/since/because” rationale was stripped, e.g. ER line 349’s “since bile-flow stimulation raises pressure behind the blockage” is absent from “Biliary obstruction or a bile duct stone”. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “Child-Pugh Class C”, “under 12 months”, “at any gestational age” and “Within 14 days of scheduled surgery” are all retained; only the non-decisional gloss “(the most advanced grade of liver failure)” was dropped. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses anywhere in the Key Interactions & Contraindications section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, which is correct — the ER names eight such populations plus one absolute drug contraindication. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eleven items are bullets from ER lines 315-339. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | The ER lists thirteen interaction bullets; the two absolute contraindications (P-glycoprotein narrow-therapeutic-index drugs, berberine supplements) are correctly routed to the stop gate, leaving exactly eleven. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eleven discrete <li> elements at QRS lines 594-610. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every Caution/Monitor verdict and mechanism sentence is stripped, and the em-dash glosses in ER lines 317, 329 and 339 (“— blood-pressure drugs”, “— stomach-acid blockers”, “Other interventions —”) are removed. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every example drug list is carried intact, including (glipizide, glyburide, gliclazide), (simvastatin, atorvastatin, lovastatin), (metoprolol, tamoxifen, codeine, many antidepressants) and (omeprazole). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | No ranking notation appears inside any parenthetical in the ER’s interaction bullets. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, which is correct — the ER documents thirteen interaction bullets. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from ER Therapeutic Protocol lines 372-384. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The three mutually non-interchangeable dosing routes — whole fruit, concentrated extract, berberine-standardized root — are the ER’s own primary structuring of the protocol. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three actionable aspects, so all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine variables carry ER-sourced content, including the timing rule “immediately before or with meals” from ER line 380 and the no-default caveat from ER line 378. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | ER line 429 names exactly three: lipid changes at 6 to 12 weeks, glucose changes at 8 weeks, endothelial function changes at 8 weeks — all three are carried. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Lipids and glucose are the ER’s two High-tier benefits and lead; endothelial function is Medium tier and follows. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist, so all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine variables are populated from ER lines 163, 171 and 429. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides explicit time-to-effect data at line 429. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All thirteen items correspond exactly to the thirteen benefit headings at ER lines 155-229. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans are present and populated at QRS lines 545-566. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading alone; every Magnitude: paragraph, mechanism sentence and trial description was dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No effect size, sample note, mechanistic hint or study parenthetical survives; the only parentheses carry the ER’s own “Conflicted” evidential flag, retained because 4.4 bars the ⚠️ glyph and 1.3 bars dropping the caveat. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers carry items in the ER, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All seven items correspond exactly to the seven risk headings at ER lines 253-295. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans are present and populated at QRS lines 622-642. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading alone; the case-control design notes, incidence ranges and albumin-binding mechanism were all dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The 2–23% frequency range, the 9.23 odds ratio and every citation parenthetical are absent; only the ER’s own “Conflicted” flag is carried. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers carry items in the ER, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The table reproduces the ER Monitoring Protocol & Defining Success biomarker table at ER lines 459-472. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 12 ER rows are present in order; a programmatic cell-by-cell comparison of name, target and why matched on 35 of 36 cells, the exception being marker_12_target, condensed but threshold-preserving. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | QRS lines 817-821 carry baseline, the 12-week panel, the 6-month repeat and the first-4-weeks daily checks, all from ER line 457. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | The five items come from the ER’s “Qualitative markers worth tracking alongside the laboratory panel” list at ER lines 476-480. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five are present and string-identical to the ER bullets. |
Issues 04/09/2026 04:23
Pass rate 100.00%. No issues found.